Abbott Laboratories (ABT) Total Current Liabilities (2009 - 2026)

Abbott Laboratories' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $18.4 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 41.32% year-over-year to $18.4 billion; the TTM figure through Mar 2026 stood at $18.4 billion (up 41.32% YoY), while the FY2025 annual figure was $16.5 billion, up 16.52% from the prior year.
• Total Current Liabilities came in at $18.4 billion for Q1 2026 at Abbott Laboratories, up from $16.5 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.4 billion in Q1 2026 to a low of $12.4 billion in Q2 2022.
• A 5-year average of $14.3 billion and a median of $14.0 billion in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities retreated 10.64% in 2023 and surged 41.32% in 2026, its largest moves.
• Abbott Laboratories' Total Current Liabilities stood at $15.5 billion in 2022, then decreased by 10.64% to $13.8 billion in 2023, then rose by 2.28% to $14.2 billion in 2024, then grew by 16.52% to $16.5 billion in 2025, then climbed by 11.4% to $18.4 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $18.4 billion, $16.5 billion, and $14.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison